Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phaos Technology Holdings CaymanPOAS -1.12%4 Net Cash per Share is $-0.27 as of Oct. 2025. GuruFocus rates POAS with a GF Score™ of 4/100. The stock has 5 warning signs investors should review. Among 301 Medical Devices & Instruments companies, Phaos Technology Holdings Cayman ranks worse than 332225.58% on this metric.
The historical rank and industry rank for Phaos Technology Holdings Cayman's Net Cash per Share or its related term are showing as below:
POAS's Price-to-Net-Cash is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 8.2 * Ranked among companies with meaningful Price-to-Net-Cash only.
Phaos Technology Holdings Cayman (AMEX:POAS) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Phaos Technology Holdings Cayman Net Cash per Share Related Terms
Phaos Technology Holdings Cayman Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phaos Technology Holdings Cayman Net Cash per Share Chart
POAS vs XAIR, LUDG, TNON: Net Cash per Share Comparison
For the Medical Devices subindustry, Phaos Technology Holdings Cayman's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phaos Technology Holdings Cayman Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Phaos Technology Holdings Cayman's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Phaos Technology Holdings Cayman's Price-to-Net-Cash falls into.
Phaos Technology Holdings Cayman Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phaos Technology Holdings Cayman (POAS) has a Net Cash per Share of $-0.27 as of Oct. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Phaos Technology Holdings Cayman and its competitors. According to the industry distribution chart, Phaos Technology Holdings Cayman ranks #999999 out of 301 companies in the Medical Devices & Instruments industry.
Is Phaos Technology Holdings Cayman's Net Cash per Share too high?
Phaos Technology Holdings Cayman's current Net Cash per Share is $-0.27. Based on the distribution chart, Phaos Technology Holdings Cayman ranks #999999 out of 301 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Phaos Technology Holdings Cayman has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Phaos Technology Holdings Cayman's Net Cash per Share compare to XAIR and LUDG?
According to the Medical Devices & Instruments industry distribution chart, Phaos Technology Holdings Cayman ranks #999999 out of 301 companies for Net Cash per Share. This places Phaos Technology Holdings Cayman in the lower half of its industry. The industry median Net Cash per Share is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 8.20, based on 301 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Phaos Technology Holdings Cayman and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phaos Technology Holdings Cayman's current Net Cash per Share is $-0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phaos Technology Holdings Cayman stock overvalued right now?
Phaos Technology Holdings Cayman (POAS) has a current Net Cash per Share of $-0.27. The current Net Cash per Share is $-0.27. Phaos Technology Holdings Cayman's overall GF Score™ is 4/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Phaos Technology Holdings Cayman (POAS), the current Net Cash per Share is $-0.27 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of advanced optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers advanced microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.
4GF Score
Get the complete analysis for POAS
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POAS has been successfully added to your 
